Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Results Conference Call August 15, 2023 8:00 AM ET

Company Participants

Naomi Aoki - Investor Relations

Michael Parini - CEO and Executive Director

Pamela Foulds - Chief Medical Officer

Paul Schneider - CFO and Director

Conference Call Participants

Luis Santos - H.C. Wainwright

Operator

Good morning, everyone, and welcome to the Freeline Second Quarter 2023 Financial and Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation there will be opportunity to ask questions. [Operator Instructions] Please also note today's event is being recorded.

At this time, I'd like to turn the floor over to Naomi Aoki, SVP of Investor Relations and Corporate Communications. Ma'am, you may begin.

Naomi Aoki

Thank you, operator, and thanks to everyone for joining us on the call. Earlier today, we issued a press release and filed our quarterly report on Form 6-K with our second quarter 2023 financial results and business updates. The release and the 6-K are both available on the Investors section of our website.

We will begin the call with prepared remarks by Michael Parini, our Chief Executive Officer; Pamela Foulds, our Chief Medical Officer; and Paul Schneider, our Chief Financial Officer. Rose Sheridan, our SVP of Research is also on the call and will be available for Q&A.

Before we begin, I would like to remind everyone that we will be making forward-looking statements. which may include our plans and expectations with respect to our research and development pipeline, clinical trials and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent annual report on Form 20-F and other periodic reports filed with the SEC. Freeline does not undertake any obligation to update any forward-looking statements made during this call.

I'd now like to turn the call over to Michael.

Michael Parini

Thanks, Naomi, and thank you, everyone, for joining us today. At Freeline, our goal is to bring life-changing gene therapies to people with chronic debilitating diseases. We strive to do this by optimizing all components of our gene therapy candidates to truly unlock with a potential in this modality.

We have taken important steps towards that goal with the dosing of the first 2 patients ever treated with FLT201, our AAV gene therapy for Gaucher. The dosing of these patients represents a significant milestone for FLT201 for Freeline and most importantly, for Gaucher patients who need and deserve better treatment options.